Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Curanex Pharmaceuticals Inc. ( (CURX) ).
On December 31, 2025, Curanex Pharmaceuticals Inc. announced that Chief Financial Officer and Treasurer Haiyan Yang resigned effective immediately, with the company stating her departure did not stem from any disagreement over its operations, policies, or practices. The same day, Curanex appointed 52-year-old finance veteran Wanjun Zhang as CFO and Treasurer effective January 1, 2026, under a two-year consulting agreement paying $20,000 annually; Zhang brings more than two decades of experience in financial reporting, compliance, and strategy, including prior senior roles at Beijing Huaxiahuitong Petty Loan Co. Ltd. and Nasdaq-listed Perfect World (Beijing) Software Co., Ltd., and his appointment comes without any related-party ties or special arrangements, signaling a straightforward leadership transition aimed at reinforcing the company’s financial reporting and regulatory compliance capabilities.
More about Curanex Pharmaceuticals Inc.
Curanex Pharmaceuticals Inc., a Nevada-based company, operates as a publicly listed business and is required to meet U.S. Securities and Exchange Commission reporting and compliance standards, necessitating experienced financial leadership to oversee its accounting, financial reporting, internal controls, and investor relations activities.
Average Trading Volume: 374,961
Technical Sentiment Signal: Strong Sell
Current Market Cap: $10.44M
For an in-depth examination of CURX stock, go to TipRanks’ Overview page.